Inhibition of porcine reproductive and respiratory syndrome virus infection by recombinant adenovirus- and/or exosome-delivered the artificial microRNAs targeting sialoadhesin and CD163 receptors

Zhu et al.
Inhibition of porcine reproductive and respiratory syndrome virus infection by recombinant adenovirus- and/or exosome-delivered the artificial microRNAs targeting sialoadhesin and CD163 receptors

Li Zhu, Hongqin Song, Xinyu Zhang, Xiaoli Xia and Huaichang Sun*

Abstract

**Background:** The current vaccines failed to provide substantial protection against porcine reproductive and respiratory syndrome (PRRS) and the new vaccine development faces great challenges. Sialoadhesin (Sn) and CD163 are the two key receptors for PRRS virus (PRRSV) infection of porcine alveolar macrophages (PAMs), but the artificial microRNA (amiRNA) strategy targeting two viral receptors has not been described.

**Methods:** The candidate miRNAs targeting Sn or CD163 receptor were predicted using a web-based miRNA design tool and validated by transfection of cells with each amiRNA expression vector plus the reporter vector. The amiRNA-expressing recombinant adenoviruses (rAds) were generated using AdEasy Adenoviral Vector System. The rAd transduction efficiencies for pig cells were measured by flow cytometry and fluorescent microscopy. The expression and exosome-mediated secretion of amiRNAs were detected by RT-PCR. The knock-down of Sn or CD163 receptor by rAd- and/or exosome-delivered amiRNA was detected by quantitative RT-PCR and flow cytometry. The additive anti-PRRSV effect between the two amiRNAs was detected by quantitative RT-PCR and viral titration.

**Results:** All 18 amiRNAs validated were effective against Sn or CD163 receptor mRNA expression. Two rAds expressing Sn- or CD163-targeted amiRNA were generated for further study. The maximal rAd transduction efficiency was 62% for PAMs at MOI 800 or 100% for PK-15 cells at MOI 100. The sequence-specific amiRNAs were expressed efficiently in and secreted from the rAd-transduced cells via exosomes. The expression of Sn and CD163 receptors was inhibited significantly by rAd transduction and/or amiRNA-containing exosome treatment at mRNA and protein levels. Both PRRSV ORF7 copy number and viral titer were reduced significantly by transduction of PAMs with the two rAds and/or by treatment with the two amiRNA-containing exosomes. The additive anti-PRRSV effect between the two amiRNAs was relatively long-lasting (96 h) and effective against three different viral strains.

**Conclusion:** These results suggested that Sn- and CD163-targeted amiRNAs had an additive anti-PRRSV effect against different viral strains. Our findings provide new evidence supporting the hypothesis that exosomes can also serve as an efficient small RNA transfer vehicle for pig cells.

**Keywords:** Porcine reproductive and respiratory syndrome virus, Receptors, Artificial microRNAs, Anti-viral effect
Background

Porcine reproductive and respiratory syndrome (PRRS) is an economically important swine disease characterized by reproductive failures in sows and respiratory syndromes in pigs of all ages [1]. Since its first outbreak in the United States and Canada in 1987, the disease has been causing heavy economic losses to the pig industry worldwide [2,3]. Although both inactivated and live-attenuated vaccines are available for PRRS control, these vaccines failed to provide sustainable protection against the disease, against heterogeneous viral strains in particular [4]. Porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped positive sense RNA virus classified within the Arteriviridae family [5,6]. In pigs, the virus targets the cells of monocyte/macrophage lineage [7,8], causing severe cell death, slow and weak antiviral responses, and/or persistent infections. In addition, PRRSV uses additional evasion strategies to escape the host innate and acquired immunity, including interference with antigen presentation, antibody-mediated infection enhancement, reduced cell surface expression of the viral proteins and shielding of the neutralizing epitopes. As a consequence, new PRRS vaccine development faces great challenges since they suffer from the immune evasion strategies of the virus and the highly antigenic heterogeneity of field viral strains [4].

PRRSV enters the target cells by receptor-mediated endocytosis [9]. To date, at least three PRRSV receptors have been identified on porcine alveolar macrophages (PAMs), including heparan sulphate as the general attachment factor, sialoadhesin (Sn or CD169) for the viral binding and internalization, and CD163 for the viral genome release [10]. Previous studies have shown that PRRSV infection of PAMs can be blocked partially by the Sn- or CD163-specific antibody or completely by a combination of two antibodies [11], and that adenoviral (Ad) vector-delivered soluble Sn and CD163 receptors have an additive effect against PRRSV infection [12]. These data suggest that the two viral receptors are the useful targets for designing new strategies for PRRS control.

RNA interference (RNAi) is a post-transcriptional gene silencing mechanism conserved in eukaryotes ranging from worms to humans [13]. Since its discovery in 1994 as an innate antiviral mechanism, RNAi has become a feasible strategy against a variety of viral infections [14]. Two types of small RNAs, namely small interfering RNAs (siRNAs) and microRNAs (miRNAs), are the central players in RNAi process, both of which inhibit gene expression by binding to the target RNA molecules [15]. A recent study has shown that viral vector-expressed artificial miRNAs (amiRNAs) are more effective than the conventional short hairpin RNA (shRNA) strategy [16,17]. Among the viral vectors available, Ads have been used extensively as the gene transfer vectors for gene therapy and vaccine development with several advantages, including efficient gene delivery, transduction of both dividing and non-dividing cells, ease of propagation to high titers, and minimal risk of genomic insertion mutagenesis [18]. In addition, Ad vectors have been used to deliver PRRSV-targeted shRNAs in vitro and in vivo [19]. However, PRRSV targets the cells of monocyte/macrophage which are resistant to rAd transduction due to the lack of high affinity Ad receptor [20]. More recently, it has been shown that the exosomes derived from human and mouse cells can serve as an efficient small RNA transfer vehicle [21]. Therefore, we hypothesized that the co-delivery of Sn- and CD163-targeted amiRNAs by rAds and exosomes could become a novel strategy against PRRSV infection.

To test the above hypothesis, in this study we predicted the candidate miRNAs targeting Sn or CD163 receptor and validated them experimentally using a reporter assay. Two rAds expressing the effective amiRNAs were generated for further study. Cell transduction assays showed that the sequence-specific amiRNAs were expressed efficiently in and secreted from rAd-transduced pig cells via exosomes. In primary PAMs, the expression of two viral receptors was inhibited significantly by transduction with the amiRNA-expressing rAd and/or treatment with the amiRNA-containing exosomes. Furthermore, PRRSV infection of PAMs was inhibited significantly by transduction with the two amiRNA-expressing rAds and/or treatment with the two amiRNA-containing exosomes. These results supported the hypothesis that simultaneous knock-down of Sn and CD163 receptors may become a novel strategy against PRRSV infection. In addition, our findings suggest that exosomes can also serve as an efficient small RNA transfer vehicle for pig cells. To our knowledge, this is the first study to explore an amiRNA strategy against PRRSV infection by targeting the two viral receptors.

Results

Prediction and validation of the miRNAs targeting Sn or CD163 receptor

Computational prediction represents an effective strategy for identification of the candidate siRNAs or miRNAs that can be validated experimentally. We analyzed the first 1751-nt sequence of porcine Sn mRNA and the 1511-nt sequence of porcine CD163 mRNA for candidate miRNAs. Ten top-scoring miRNA sequences for each target were reported and 18 of them (Table 1) were selected for amiRNA vector construction (Figure 1A). To facilitate the candidate miRNA validation, the first 1751-bp sequence of the Sn cDNA or the 1511-bp sequence of the CD163 cDNA was cloned in frame with the green fluorescent protein (GFP) coding sequence in...
Table 1 The oligonucleotides used for construction of amiRNA expression vectors in this study

| Target | miRNA | Start | Double-stranded oligonucleotide sequence (5′→3′) |
|--------|-------|-------|----------------------------------|
| Sn     | 1     | 161   | TCCTCACTGACAGACATGCGCTGTGCACTCTCGTAAGCCTCACTCACAATGTCGTAATCTACCTGATGAGCTTCTGACATGCTGACAAGAGAGATGGTGTCAGTCAGTGGCCAAAACCTGGAGGTGGACTTCAACTC |
|        | 2     | 367   | CGTTTTGGCCACTGACTGACAACCGCTGCAGATGTCAAAACCCAGGATGTCAAAGGAGACTTCACCTTC |
|        | 3     | 378   | CGTTTTGGCCACTGACTGACAGATGTCAGGCACAGTTGT |
|        | 4     | 458   | CGTTTTCGAGTTGAAGTCCCTCCATGCGTGTCAGTCAGTGGCCAAAACACGCAGGATGGACATGCTGACATGCTGACAAGAGAGATGGTGTCAGTCAGTGGCCAAAACCTGGAGGTGGACTTCAACTC |
|        | 5     | 461   | CGTTTTCGAGTTGAAGTCCCTCCATGCGTGTCAGTCAGTGGCCAAAACACGCAGGATGGACATGCTGACATGCTGACAAGAGAGATGGTGTCAGTCAGTGGCCAAAACCTGGAGGTGGACTTCAACTC |
|        | 6     | 669   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 7     | 1148  | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 8     | 1476  | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 9     | 1510  | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 10    | 1486  | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
| CD163  | 1     | 94    | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 2     | 527   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 3     | 645   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 4     | 740   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 5     | 768   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 6     | 807   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 7     | 961   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 8     | 998   | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 9     | 1325  | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |
|        | 10    | 1486  | CGTTTTGGCCACTGACTGACCTGGATCTGGAGGTATGCTTCACTTC |

The candidate amiRNAs were predicted by following the instructions for the web-based Block-iTTM RNAi designer. The mature amiRNA and forward primer sequences for the detection of amiRNAs in rAd-transduced cells are indicated as italics.
pEGFP-N1 vector to produce the reporter vector pSn-GFP or pCD163-GFP (Figure 1B). NIH 3 T3 cells were co-transfected with each amiRNA expression vector and the reporter vector, and the cell culture was assayed for GFP+ cells by flow cytometry. By using pSn-GFP-transfected cells as the reference, transfection with each amiRSn expression vector plus the reporter vector resulted in GFP+ cell number reductions ranging from 39.6% to 96.3% (Figure 1C). Similarly, transfection with each amiRCD163 expression vector plus the reporter vector led to GFP+ cell number reductions ranging from 53.3% to 88.5% (Figure 1D). The most effective amiRSn-2 and amiRCD163-2, as well as an irrelevant amiRcon (Table 1), were selected for further study.

rAd generation and cell transduction
We subcloned amiRSn-2, amiR163-2 or amiRcon expression cassette into Ad vector pShuttle-IRES-hrGFP, and three rAds, namely rAd-amiRSn, rAd-amiR163 and rAd-amiRcon, were generated by transfecting AAV-293 cells with the rAd vectors (Figure 2A). Primary PAMs and PK-15 cells were transduced with different doses of rAds, and the cell cultures were analyzed for GFP+ cells by flow cytometry. By using pSn-GFP-transfected cells as the reference, transfection with each rAd resulted in GFP+ cell number reductions ranging from 39.6% to 96.3% (Figure 1C). Similarly, transfection with each rAdCD163 expression vector plus the reporter vector led to GFP+ cell number reductions ranging from 53.3% to 88.5% (Figure 1D). The most effective amiRSn-2 and amiRCD163-2, as well as an irrelevant amiRcon (Table 1), were selected for further study.

The sequence-specific amiRNAs were expressed in and secreted from the rAd-transduced cells
To investigate whether the amiRNAs were expressed in rAd-transduced cells, primary PAMs or PK-15 cells were transduced with rAd-amiRSn, rAd-amiRCD163 or rAd-amiRcon, and the total RNA was extracted 48 h after transduction. At the same time, the exosomes were purified from cell culture medium and the total RNA was extracted for sequence-specific amiRNA detection. The expected 80-nt amiRNAs were detected in all of the three rAd-transduced cells (Figure 3A) and their exosomes (Figure 3B), but not in the mock-transduced cells and their exosomes.

The rAd- and exosome-delivered amiRNA had an additive effect against the target gene expression
The sufficient knock-down of Sn and CD163 receptors is the precondition for the objective evaluation of anti-PRRSV effects of the receptor-targeted amiRNAs. We compared the knock-down efficiencies of the two viral receptors using three different strategies: rAd transduction, exosome treatment and rAd transduction plus exosome treatment. First, primary PAMs were transduced with rAd-amiRSn, rAd-amiR163 or rAd-amiRcon. After incubation for 48 h, the total RNA was extracted for mRNA detection by quantitative RT-PCR and the cell culture was analyzed for Sn+ or CD163+ cell number by flow cytometry. Compared to that in rAd-amiRcon-transduced
cell cultures, Sn or CD163 receptor mRNA expression in the rAd-amiRSn- or rAd-amiRCD163-transduced cells was decreased by 0.51 or 0.54 fold (Figure 4A), while Sn⁺ and CD163⁺ cell numbers were decreased from 48.7% to 22.7% and from 49.9% to 27.6%, respectively (Figure 4B). Next, primary PAMs were incubated with the exosomes (0.5 mg protein/ml) derived from rAd-amiRSn- or rAd-amiRCD163-transduced PK-15 cells. At 48 h after incubation, the total RNA was extracted for quantitative RT-PCR and the cell cultures were harvested for flow cytometry analysis as described. Compared to that in the two control groups, Sn or CD163 mRNA expression in the amiRNA-containing exosome-incubated cells was decreased by 0.41 or 0.46 fold (Figure 4A), while Sn⁺ and CD163⁺ cell numbers were decreased to 33.4% and 36.5%, respectively (Figure 4B). Finally, primary PAMs were transduced first with each rAd, incubated for 48 h with each amiRNA-containing exosomes, the total RNA was extracted for quantitative RT-PCR and the cell cultures were harvested for flow cytometry analysis as described. Compared to that in the two control groups, Sn or CD163 mRNA expression was decreased by 0.73 or 0.73 fold (Figure 4A), while Sn⁺ and CD163⁺ cell numbers were decreased to 18.9% and 19.1%, respectively (Figure 4B).

**Sn and CD163 receptor-targeted amiRNAs had an additive effect against PRRSV infection**

We used two different quantitative assays to evaluate the additive anti-PRRSV effect between Sn and CD163 receptor-targeted amiRNAs: quantitative RT-PCR and viral titration. For the quantitative RT-PCR, primary PAMs were transduced with rAd-amiRcon, rAd-amiRSn and/or...
rAd-amiRCD163 as described, and infected with PRRSV strain VR2332 (MOI 0.2) 48 h after transduction. At 24 h post infection, the total RNA was extracted for quantitative RT-PCR using PRRSV ORF7-specific primers (Table 2). Compared to that (5.4 log10) in rAd-amiRcon-transduced cells, the ORF7 copy number in rAd-amiRSn and/or rAd-amiRCD163 transduced cells was decreased by 3.5, 2.3 or 2.6 log10 (Figure 5). Next, primary PAMs were incubated with the exosomes derived from rAd-amiRSn- and/or rAd-amiRCD163-transduced PK-15 cells, infected with PRRSV and the total RNA was extracted for quantitative RT-PCR as described. Compared to that (5.4 log10) in the control group, the ORF7 copy number in amiRSn- and/or amiRCD163-containing exosome-incubated cells was decreased by 3.3, 2.0 or 2.2 log10 (Figure 5). Finally, primary PAMs were transduced with different rAds, incubated with different amiRNA-containing exosomes, infected with PRRSV and total RNA was extracted for RT-PCR as described. Compared to that (5.4 log10) in the control group, the ORF7 copy number in double rAd-transduced and double amiRNA-containing exosome-incubated cells was decreased by 4.2 log10, while the ORF7 copy number in single rAd-transduced and single amiRNA-containing exosome-incubated cells was decreased by 3.3 or 3.6 log10 (Figure 5).

For the viral titration assay, primary PAMs were transduced with different rAds and infected with PRRSV strain VR2332 as described. At different time points post infection, the cells were harvested for PRRSV titration on MARC-145 cells. Compared to that (4.3 log10 TCID_{50}) in the mock- or rAd-amiRcon-transduced cells, the PRRSV titer in rAd-amiRSn- and/or rAd-amiRCD163-transduced cells was decreased by 1.5, 0.9 or 1.0 log10 at 24 h post infection (Figure 6A). Next, primary PAMs were incubated with amiRSn- and/or amiRCD163-containing exosomes, infected with PRRSV and harvested for PRRSV titration as described. Compared to that (4.3 or 4.2 log10 TCID_{50}) in the mock- or amiRcon-containing exosome-treated cells, PRRSV titer in amiRSn- and/or amiRCD163-containing exosome-incubated cells was decreased by 1.2, 0.6 or 1.0 log10 (Figure 6B). Then, primary PAMs were transduced with different rAds, incubated with different amiRNA-containing exosomes, infected with PRRSV and harvested for PRRSV titration as described. Compared to that (4.3 or 4.4 log10 TCID_{50}) in the two control groups, the PRRSV titer in double rAd-transduced and double amiRNA-containing exosome-incubated cells was decreased by 2.0 log10, while the viral titer in single rAd-transduced and single amiRNA-containing exosome-incubated cells was decreased by 1.1 log10 (Figure 6C). The similar additive
anti-PRRSV effect between the two amiRNAs lasted for at least 96 h (Figure 6A, B or C). Finally, primary PAMs were transduced with different rAds, incubated with different amiRNA-containing exosomes and infected with PRRSV strain JX-A1, CH-1R or VR2332 as described. At 72 h post infection, the infected cells were harvested for PRRSV titration. Compared to that (4.9–6.2 log10 TCID50) in the two control groups, the PRRSV titers in three viral strain-infected cells were decreased by 2.7, 2.1 and 2.6 log10, respectively (Figure 6D).

**Discussion**

As a natural antiviral mechanism, RNAi has become a feasible strategy against a variety of viral infections [13], but its in vivo use is limited by the low efficiency of small RNA delivery. Such drawbacks can be alleviated by using viral vectors for small RNA delivery. Among the viral vectors available, Ads have several advantages and thus have been used extensively as the gene transfer vectors for gene therapy and vaccine development [18]. Furthermore, Ads have been shown to an efficient shRNA delivery vehicle for pig cells [19]. Therefore, in this study we used rAd vectors as the amiRNA delivery vehicle. Cell transduction experiments showed that the human Ad5-based vectors could not only transduce pig cells (Figure 2), but also express the encoded amiRNAs efficiently (Figure 3). Unlike pig kidney PK-15 cells, however, primary PAMs were resistant to rAd transduction and only a maximal transduction efficiency of about 60% was achievable by using very high doses (MOI ≥ 800) of...
rAd vectors (Figure 2). This could be explained by the lack of high affinity Ad receptor on primary PAMs, which has been reported for the primary macrophages in other species [20].

As a natural mechanism in animal cells, the exosomes derived from human and mouse cells can serve as an efficient vehicle for small RNA transfer [21]. In the light of resistance of PAMs to rAd transduction, this warranted us to explore the feasibility of pig cell-derived exosomes as a small RNA delivery vehicle, which has not been reported in livestock such as pigs. Our RT-PCR assay showed that the sequence-specific amiRNAs were easily detected in the exosomes purified from the cell culture medium of rAd-transduced pig cells (Figure 3B), indicating that the viral vector-encoded amiRNAs were secreted from the pig cells via exosomes. Furthermore, the sequence-specific amiRNAs were detected in the exosome-incubated PAMs (data not shown) and showed significant inhibitory effects against PRRSV infection (Figures 5 and 6). These results suggested that exosomes could also serve as an efficient small RNA transfer vehicle for pig cells.

PRRSV uses at least three receptors to enter PAMs, among which Sn and CD163 play essential but different roles [10]. It has been shown that PRRSV infection of PAMs can be blocked partially by Sn- or CD163-specific antibody, or completely by a combination of two antibodies [11]. Our previous study has also shown that the soluble Sn and CD163 receptors have an additive effect against PRRSV infection [12]. These indicate that the simultaneous knock-down of two viral receptors is required to achieve a significant antiviral effect. In the light of resistance of PAMs to rAd transduction, we compared Sn and CD163 receptor knock-down efficiencies of three different strategies: rAd transduction, exosome treatment and rAd transduction plus exosome treatment. Both quantitative RT-PCR and flow cytometry analyses showed that, compared to the lower knocking-down efficiency of Sn or CD163 receptor by rAd transduction or exosome treatment, the rAd transduction plus exosome treatment resulted in significantly more knock-down of the two viral receptors at both mRNA and protein levels (Figure 4). These results suggested that exosomes could assist rAds to deliver small RNAs into pig cells, which was particularly important for the delivery of amiRNAs into PAMs that were resistant to rAd transduction.

Similarly, we used the three different strategies to investigate the additive anti-PRRSV effect between Sn and CD163 receptors.

Table 2 The primers used for PCR or real-time quantitative PCR in this study

| Gene  | Primer pair | Sequence (5′→3′) | Amplicon (bp) |
|-------|-------------|------------------|---------------|
| Sn    | For1        | CTAGATCTATGGACTTCTGCTTCTGCTGCT | 1751          |
|       | Rev1        | AGCGAGCGAAGCGAAG | 201           |
|       | For2        | TCTGGTCTTGGACCTGCTGCTGCT | 110           |
| CD163 | For1        | CTTCGAGATGTGACTTCGAGACTC | 1511          |
|       | Rev1        | CGGATTTCCAGAGAGAAGTGCAGAAGTGCAGAAG | 208           |
|       | For2        | ATTCATCTTGGACCTGCTGCTGCTGCTGCT | 308           |
| PRRSV | For         | CCAGCCAGTGCACTTAC | 90            |
| GADPH | For         | ACACTCAAATTCATTGTACCACCAG | 308           |

Figure 5 Detection of PRRSV ORF7 copy numbers in rAd-transduced and/or exosome-incubated PAMs. Primary PAMs were transduced with single or double rAds and/or incubated for 48 h with single or double amiRNA-containing exosomes. The cells were infected with PRRSV strain VR-2332 and the total RNA was extracted 24 h post infection for ORF7 copy number detection by real time quantitative RT-PCR.
CD163 receptor-targeted amiRNAs. Quantitative RT-PCR showed that the simultaneous knock-down of two viral receptors resulted in more reductions in PRRSV ORF7 copy number than the single receptor knock-down (Figure 5). In addition, much more reduction in the ORF7 copy number was achieved by using rAd transduction plus exosome treatment (Figure 5). The similar results were obtained from viral titration assays (Figure 6,B and C). The additive anti-PRRSV effect between the two viral receptor-targeted amiRNAs was relatively long-lasting (96 h) and effective against all three different viral strains tested (Figure 6D). However, the complete inhibition was not achieved by using three different strategies and very high rAd doses (MOI ≥ 800) for cell transduction. This could be explained by the following reasons: first, Sn and/or CD163 receptor-targeted amiRNAs delivered by three different strategies were insufficient for the complete knock-down of two viral receptors (Figure 4) due to the inherent incomplete knock-down of RNAi strategy [22], and/or the resistance of primary PAMs to rAd transduction [20]. Second, the turnover of Sn and/or CD163 receptor was longer than that we tested (48 h) and thus the certain amounts of pre-expressed receptors were present on the rAd-transduced and/or exosome-incubated PAMs. Finally, there were alternative cellular factor (s) may be involved in PRRSV infection of primary PAMs. Among these, CD151 may be an important one since it plays an

![Figure 6 Titration of PRRSV titers in rAd-transduced and/or exosome-incubated PAMs.](image-url)

(A) Primary PAMs were transduced with different rAds and infected with PRRSV strain VR2332 48 h after transduction. At different time points after infection, the cells were harvested for PRRSV titration on MARC-145 cells. (B) Primary PAMs were incubated for 48 h with different amiRNA-containing exosomes and then infected with PRRSV strain VR2332 before PRRSV infection and titration. (C) Primary PAMs were transduced with different rAds and then incubated for 48 h with different amiRNA-containing exosomes before PRRSV infection and titration. (D) Primary PAMs were transduced with different rAds and then incubated for 48 h with different amiRNA-containing exosomes. The cells were infected with three different PRRSV strains and harvested for PRRSV titration 72 h after infection.
important role in PRRSV infection of MARC-145 cells and is expressed on primary PAMs [23,24]. These warrant us to refine the amiRNA strategy by targeting more cellular factors and/or using more efficient amiRNA transfer vectors such as recombinant lentiviruses.

Both Sn and CD163 receptors are macrophage-restricted cell surface molecules that are conserved across mammals. Among these, Sn receptor is a member of the sialic acid-binding IgG-like lectin family of proteins which contributes to sialylated pathogen uptake, antigen presentation and lymphocyte proliferation [25], while CD163 receptor is a critical for the efficient extracellular hemoglobin clearance during hemolysis [26]. Therefore, whether the knock-down of two receptors could influence the viability or compromise the cell functions of PAMs should be considered. In the light of the fact that expression of the two receptors are regulated by several factors such as glucocorticoids and IL-10, and that the expression levels vary significantly under different conditions [15,26], we speculated that the two genes were not vital for the cell viability. This speculation was supported by an additional fact that the viability of PAM cell lines is not compromised by the loss of Sn and/or CD163 expression [27]. In any case, more studies are certainly needed to address the safety of our amiRNA strategy before its in vivo use.

In summary, in this study we generated two rAds expressing Sn or CD163 receptor-targeted amiRNA and investigated their anti-PRRSV effect using different strategies. The Ad vectors could not only transduce different pig cells, but also express the vector-encoded amiRNAs. The vector-expressed amiRNAs were secreted from Ad-transduced cells via exosomes not only, but taken up by other pig cells as well. A significant additive anti-PRRSV effect between the two amiRNAs was demonstrated by transduction of PAMs with the two rAds or by incubation with the two amiRNA-containing exosomes, which was enhanced further by co-transduction with the two rAds plus co-incubation with the two amiRNA-containing exosomes. Although the complete anti-PRRSV effect has not yet been demonstrated, this study may facilitate further works on development of more efficient strategies against PRRS.

Conclusion
This study demonstrated that Sn and CD163 receptor-targeted amiRNAs had an additive anti-PRRSV effect against different viral strains. In addition, we provided new evidence that the exosomes could serve as an efficient small RNA deliver vehicle for pig cells.

Methods
Cells, viruses and reagents
Mouse fibroblast cell line L-929 (ATCC CCL-1) was grown in Dulbeccos Modified Eagles Medium (DMEM)/Nutrient Mixture F-12 (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) and 1% non-essential amino acids. Pig kidney cell line PK-15 (ATCC CCL-33), mouse embryo fibroblast cell line NIH 3 T3 (ATCC CRL-1658), AA.V-293 cells (Stratagene, USA) and African green monkey kidney cell line MARC-145 cells (ATCC CRL-12231) were grown in DMEM supplemented with 10% FBS and 1% non-essential amino acids. Primary PAMs were prepared from 6-week-old Lancraces pigs as described previously [7] and grown in DMEM/F-12 supplemented with 10% FBS, 1% non-essential amino acids and 20% L-929-conditioned medium. PRRSV strain VR-2332 (ATCC VR2332) is a prototype strain of North American genotype [28]. PRRSV strain CH-1a is a highly pathogenic Chinese strain [29]. PRRSV strain JX-A1 is a highly pathogenic Chinese strain [30]. The three PRRSV strains were propagated and titrated on MARC-145 cells.

miRNA prediction and double-strand oligonucleotide preparation
The first 1751-nt sequence of porcine Sn mRNA (GenBank: AF505985) and the 1511-nt sequence of porcine CD163 mRNA (GenBank: NM_213976) were predicted using the web-based BLOCK-iT®RNAi designer (Invitrogen, USA). Among 10 top-scoring sequences reported for each target, 18 of them were selected for miRNA design according to their higher knock-down probabilities (star rankings). The top- and bottom-strand oligonucleotides (Table 1) were synthesized, each pair of them (5 μl, 200 μM) was denatured at 94°C for 5 min and slowly annealed at room temperature to form double-strand oligonucleotide.

Vector construction
For construction of the amiRNA expression vectors, each double-strand oligonucleotide was cloned at the BbsI site of amiRNA expression vector pcDNA-miR [31], in which the amiRNA expression cassette consists of the 5’- and 3’-miR flanking sequences of mouse BIC non-coding mRNA, followed by the poly(A) signal of human herpesvirus TK gene (Figure 1A). The recombinant vectors, namely pcDNA-miRSn (1 9), pcDNA-miRCD163 (1 9) or control pcDNA-miRcon, were used for amiRNA validation.

For construction of the reporter vectors, the cellular RNA was extracted from primary PAMs using RNAiso Plus (KaTaRa, Dalian, China) according to the manufacturer’s instructions. The reverse transcription (20 μl) was performed using RevertAid™Reverse Transcriptase (Fermentas, USA) by following the manufacturer’s
protocol. The PCR (50 μl) was performed using 5 μl of RT product and LA Taq DNA Polymerase (KaTaRa, Dalian, China) according to the manufacturers manual. The first 1751-bp Sn cDNA segment was amplified using primers Sn For1 and Sn Rev1 (Table 2). The PCR was carried out at 94°C for 5 min; 30 cycles of 94°C for 45 sec, 60°C for 45 sec and 72°C for 2 min; and a final extension at 72°C for 10 min. The first 1511-bp CD163 cDNA segment was amplified using primers CD163 For1 and CD163 Rev1 (Table 2). The PCR was carried out at 94°C for 5 min; 30 cycles of 94°C for 45 sec, 50°C for 45 sec and 72°C for 1.5 min; and a final extension at 72°C for 10 min. Each PCR product was cloned into pMD18-T vector for sequencing and then at the XhoI/BamHI site of pEGP-N1 vector (Invitrogen, USA) to produce reporter vector pSn-EGFP or pCD163-EGFP (Figure 1B). The expression of two GFP fusions was checked by transfection of NIH 3 T3 cells and fluorescent microscopy.

For construction of the rAd vectors, the amiRSn-2, amiRCD163-2 or amiRcon expression cassette was excised from the amiRNA expression vector by restriction digestion with AatII and PvuI, and cloned into pShuttle-IREShrGFP (Stratagene, USA) vector after linearization with the same enzymes. The pShuttle-IREShrGFP vector is rendered replication defective by deletion of the E1 and E3 genes [32], and by inclusion of humanized Renilla reniformis GFP (hrGFP) sequence after the internal ribosome entry site (IRES) for follow-up purpose. The resultant rAd vector was called pShuttle-amiRSn-IREShrGFP, pShuttle-amiRCD163-IREShrGFP or pShuttle-amiRcon-IREShrGFP (Figure 2A).

**Candidate amiRNA validation**

NIH 3 T3 cells were seeded in triplicates at 5 × 10⁵/well on 24-well plates and grown to 70% confluent growth. The cells were transfected with pcDNA-amiRSn (1 g), pcDNA-amiRCD163 (1 g) or pcDNA-amiRcon (2 μg/well) plus pSn-EGFP or pCD163-EGFP (0.4 μg/well). The transfection was performed using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s manual. At 24 h after transfection, the cells were trypsinized, washed three times with PBS, diluted to 10⁶ cells/ml and analyzed (10⁴ cells) for total fluorescence and cell numbers on BD FACSAria III (BD, USA). The effectiveness of each amiRNA was expressed as the percent inhibition of Sn-GFP or CD163-GFP fusion expression using pSn-GFP- or pCD163-GFP-transfected as the reference.

**rAd preparation and cell transduction**

The three rAdS, namely rAd-amiRSn, rAd-amiRCD163 and rAd-amiRcon, were generated by transfecting AAV-293 cells (Stratagene, USA) with the rAd vectors according to the instruction manual for AdEasy Adenoviral Vector System (Agilent Technologies, USA). The rAdS were amplified on AAV-293 cells, purified using ViraBind Adenovirus Miniprep Kit (CELL BIOLABS, USA) by following the manufacturers protocol, and titrated on AAV-293 cells as fluorescent formation units (FFU)/ml. For transduction of PK-15 cells, the cells were seeded in triplicates at 5 × 10⁴ cells/well on 24-well plates, and grown to 80% confluent growth. After two time wash with PBS, the cells were transduced (37°C for 2 h) with different doses (MOI) of rAdS. The transduction of primary PAMs was carried out as previously described [33]. Briefly, the cells were cultured for 7 days in the growth medium conditioned with 20% of L-929 cell culture medium. The cells were trypsinized, diluted to 10²cells/ml with the same medium, mixed with different doses of rAdS and centrifuged at 2000 g for 1 h at 37°C. After wash again with PBS, the cells were grown for additional 48 h in the fresh medium and assayed for GFP-positive cells on BD FACS Aria III or by fluorescent microscopy.

**Exosome purification**

Exosome purification was performed as previously described [34]. Briefly, primary PAMs and PK-15 cells were seeded in T75 flasks and grown to 70% confluent growth in the medium supplemented with 10% exosome-depleted FBS. The cells were transduced with each rAd (MOI 800 for primary PAMs or 100 for PK-15 cells) and incubated for additional 48 h. The cell medium was collected and centrifuged at 4C, 300 g for 10 min, 1000 g for 30 min, 10,000 g for 45 min to remove the cell debris. After filtration through a 0.22-μm filter membrane, the exosomes were precipitated by centrifugation at 120,000 g for 70 min and suspend in PBS for immediate use or stored at 80°C for later use.

**Poly(A)-tailed RT-PCR**

The poly(A)-tailed RT-PCR for amiRNA detection was performed using One Step Prime Script miRNA cDNA Synthesis Kit (KaTaRa, Dalian China) by following the manufacturers protocol. Briefly, the total RNA was extracted from rAd-transduced cells or purified exosomes for cDNA synthesis. Each amiRNA cDNA was amplified using the sequence-specific forward primer (Table 1) and the general reverse primer in the cDNA synthesis kit. The PCR was carried out at 95°C for 30 sec, 35 cycles of 95°C for 10 sec, 58°C for 30 sec, 72°C for 10 sec, and a final extension at 72°C for 5 min. The PCR products (8 μl) were analyzed by electrophoresis on a 3% agarose gel.

**Quantitative RT-PCR**

The real-time quantitative RT-PCR for Sn and CD163 receptor mRNA detection was performed as described previously [35]. Briefly, primary PAMs were transduced in triplicates with each rAd and incubated in the medium with or without the exosomes (0.5 mg protein/ml) purified from
the rAd-transduced PK-15 cells. At 48 h after incubation, the total RNA was extracted for reverse transcription using RevertAid™ Reverse Transcriptase (Fermentas, USA). The Sn and CD163 receptor mRNA expression was analyzed by SYBR green-based real-time quantitative PCR using Roche LightCycler Nano system. The mRNA copy number was normalized by comparing to house-keeping GAPDH copy number. The primer sequences are listed in Table 2.

The real-time quantitative RT-PCR for PRRSV ORF7 copy number detection was performed as previously described [36]. Briefly, primary PAMs were transduced in triplicates with different rAds and/or incubated in the growth medium with or without the exosomes derived from rAd-transduced cells as described. At 48 h after incubation, the cells were infected with PRRSV (MOI 0.2), incubated for additional 24 h and total RNA was extracted for reverse transcription and real-time quantitative PCR as described. The standard curve was generated by comparing to PRRSV ORF7-containing plasmid [36]. The primer sequences are listed in Table 2.

**Flow cytometry analysis for detection of Sn and CD163 receptor knock-down**

The flow cytometry for detection of Sn and CD163 receptor knock-down was performed as previously described [37]. Briefly, primary PAMs were transduced in triplicates with different rAds and/or incubated for 48 h with or without the exosomes derived from rAd-transduced cells. The cells were stained with Sn- or CD163-specific antibody and analyzed by flow cytometry as described.

**PRRSV infection and titration**

Primary PAMs were seeded at 2 \( \times 10^5 \) /ml on 24-well plates and grown overnight in the medium supplemented with 10% exosome-depleted FBS. The cells were mock-transduced in triplicates or transduced with different rAds and/or incubated for 48 h with or without the exosomes (0.5 mg protein/ml) purified from different rAd-transduced PK-15 cells. The cells were infected with PRRSV strain VR-2332, CH-1R or JX-A1 (MOI 0.2) and harvested at different time points for PRRSV titration on MARC-145 cells as previously described [38].

**Abbreviations**

PRRS: Porcine reproductive and respiratory syndrome; PRRSV: Porcine reproductive and respiratory syndrome virus; siRNA: Small interfering RNA; miRNA: microRNA; FBS: Fetal bovine serum; DMEM: Dulbecco modified eagle’s medium; PCR: Polymerase chain reaction; RT-PCR: Reverse transcriptase PCR; MOI: Multiplicity of infection; TCID50: 50% tissue culture infective dose.

**Competing interests**

The authors declare that they have no competing interest.

**Authors contributions**

LZ and HQS performed the experiments; XYZ and XLX provided important reagents; LZ wrote the manuscript; HCS provided overall supervision and financial support and edited the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

This work was financially supported by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions, and the fund from the Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Diseases and Zoonoses.

**Received:** 28 July 2014 **Accepted:** 10 December 2014

---

**References**

1. Done SH, Paton DJ: Porcine reproductive and respiratory syndrome: clinical disease, pathology and immunosuppression. Vet Rec 1995, 136:32 35.
2. Neumann EJ, Klebeinstein JB, Johnson CD, Mabry JW, Bush EJ, Setzenger AH, Green AL, Zimmerman JJ: Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. J Am Vet Med Assoc 1995, 207:2385-2392.
3. Lunnery JK, Benfield D, Rowland RR: Porcine reproductive and respiratory syndrome virus: an update on an emerging and re-emerging viral disease of swine. virus Res 2010, 154:1-6.
4. Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zurwieden N: Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccines. Vaccine 2009, 27(28):3704-3718.
5. Snijder EJ, Meulenberg JJ: The molecular biology of arborviruses. J Gen Virol 1998, 79:961-979.
6. Dokland T: The structural biology of PRRSV. Virus Res 2010, 154:1-2186 97.
7. Duan X, Nauwync HJ, Pensaert MB: Effects of origin and state of differentiation and activation of monococytes/macrophages on their susceptibility to porcine reproductive and respiratory syndrome virus (PRRSV), Arch Virol 1997, 142(12):2483-2497.
8. Lee YJ, Park CK, Nam E, Kim SH, Lee OS, Lee du S, Lee C: Generation of a porcine alveolar macrophage cell line for the growth of porcine reproductive and respiratory syndrome virus. J Virol Methods 2010, 163(2):410-415.
9. Nauwync HJ, Duan X, Favorreel HW, Van Ostveld P, Pensaert MB: Entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages via receptor-mediated endocytosis. J Gen Virol 1999, 80(Pt 2):297-305.
10. Van Breedam W, Verbeck M, Christiaens I, Van Gorp H, Nauwync HJ: Porcine, murine and human sialoadhesin (Sn/Siglec-1/CD169); portals for porcine reproductive and respiratory syndrome virus entry into target cells. J Gen Virol 2013, 94(Pt 9):1955-1960.
11. Van Gorp H, Van Breedam W, Delputte PL, Nauwync HJ: Sialoadhesin and CD163 join forces during entry of the porcine reproductive and respiratory syndrome virus. J Gen Virol 2008, 89(Pt 12):2943-2953.
12. Chen Y, Guo R, He S, Zhang XY, Xia XL, Sun HC: Additive inhibition of porcine reproductive and respiratory syndrome virus infection with the soluble sialoadhesin and CD163 receptors. Virus Res 2014, 179:85-92.
13. Fire A: RNA triggered gene silencing. TIG 1999, 15:358-363.
14. Zhou J, Rossi JJ: Progress in RNAi-based antiviral therapeutics. Methods Mol Biol 2011, 721:57-75.
15. Terazawa K, Shimizu K, Tsujimoto G: Synthetic pre-miRNA-based shRNA as potent RNAi triggers. J Nucleic Acids 2011, 2011:1-6.
16. Boden D, Fuch O, Silbermann M, Lee F, Tucker L, Ramratnam B: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004, 32:1154-1158.
17. Liu YP, Hassanoit J, ter Brake O, Berkhaul B, Konstantinova P: Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008, 36:2811-2824.
18. Khare R, Khare R, Chen CY, Weaver EA, Barry MA: Advances and further challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011, 11(4):241-258.
19. Li G, Jiang P, Li Y, Wang X, Huang J, Bai J, Cao J, Wu B, Chen N, Zeshan B: Inhibition of porcine reproductive and respiratory syndrome virus replication by porcine microRNA-mediated RNA interference both in porcine alveolar macrophages and swine. Antiviral Res 2009, 82(2):157-165.
20. Kaner RJ, Worollal S, Leopold PL, Stolze E, Milano E, Hidaka C, Ramalingam R, Hackett NR, Singh R, Bergelson J, Finberg R, Falck-Pedersen E, Crystal RG: Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but insufficient, limited in part by
the low level of expression of the coxackie/adenoivirus receptor. Am J Respir Cell Mol Biol 1999, 20(3):361 370.

21. Valadi H, Ekstrom K, Bossios A, Sjstrand M, Lee JJ, Ltvall JO: Exosome mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9(6):564 659.

22. Zhang H, Li HC, Xiao XX: Feasibility, limitation and possible solutions of RNAi-based technology for insect pest control. Insect Sci 2013, 20(1):15 30.

23. Shamshukhappa K, Kim J, Kapil S: Role of CD151, A tetraspanin, in porcine reproductive and respiratory syndrome virus infection. Virol J 2007, 4:62.

24. Huang Y, Guo R, Zhang Y, Zhang X, Xia X, Sun H: Establishment of a porcine CD151 transgenic PK-15 cell line susceptible to porcine reproductive and respiratory syndrome virus. Wei Sheng Wu Xue Bao 2013, 53(5):507 514.

25. Chang YC, Olson J, Louie A, Crocketer PR, Varki A, Nizet V: Role of macrophage sialoadhesin in host defense against the sialylated pathogen group B Streptococcus. J Mol Med (Berl) 2014, 92(9):951 959.

26. Komori H, Watanabe H, Shuto T, Kodama A, Maeda H, Watanabe K, Kai H, Otogin M, Manuyama T: α(1)-Acid glycoprotein up-regulates CD163 via TLR4/CD14 protein pathway: possible protection against hemolysis-induced oxidative stress. J Biol Chem 2012, 287(56):30088 30099.

27. Lee YJ, Park OK, Nam E, Kim SH, Lee OS, du Lee S, Lee C: Generation of a porcine alveolar macrophage cell line for the growth of porcine reproductive and respiratory syndrome virus. J Virol Methods 2010, 163(2):410 415.

28. Collins JE, Benfield DA, Christianson WT, Harris L, Hennings JC, Shaw DP, Goyal SM, McCullough S, Morrison RB, Joo HS, Gorczyca D, Chaldek D: Isolation of swine infertility and respiratory syndrome virus (isolate ATCC VR-2332) in North America and experimental reproduction of the disease in gnotobiotic pigs. J Vet Diagn Invest 1992, 4(2):117 126.

29. Hu S, Zhang Z, Cai X, Tian Z, Liu Y, An T, Wu D: Validation of protective efficacy of PRRS attenuated vaccine and inactivated mutant PRRSV strains. Chin J Prev Vet Med 2009, 31(3):392 396.

30. Tian K, Yu X, Zhao T, Feng Y, Gao Z, Wang C, Hu Y, Chen X, Hu D, Tian X, Liu D, Zhang S, Deng X, Ding Y, Yang L, Zhang Y, Xiao H, Qiao M, Wang B, Hou L, Wang X, Yang X, Kang L, Sun M, Jin P, Wang S, Kitamura Y, Yan J, Gao GF: Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS One 2007, 2(6):e262.

31. Xia B, Song H, Chen Y, Zhang X, Xia X, Sun H: Efficient inhibition of porcine reproductive and respiratory syndrome virus replication by artificial microRNAs targeting the untranslated regions. Arch Virol 2013, 158(1):51 61.

32. Benihoud K, Yeh P, Perricaudet M: Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999, 10(5):440 447.

33. Mayne GC, Borowicz RA, Greeneklee KV, Finlay-Jones JJ, Williams KA, Hart PH: Centrifugation facilitates transduction of green fluorescent protein in human monocytes and macrophages by adenovirus at low multiplicity of infection. J Immunol Methods 2003, 278(1 2):45 56.

34. Han X, Fan S, Patel D, Zhang YJ: Enhanced inhibition of porcine reproductive and respiratory syndrome virus replication by combination of morpholino oligomers. Antiviral Res 2009, 82:59 66.

35. Wang L, Zhang H, Suo X, Zheng S, Feng WH: Increase of CD163 but not sialoadhesin on cultured peripheral blood monocytes is coordinated with enhanced susceptibility to porcine reproductive and respiratory syndrome virus infection. Vet Immunol Immunopathol 2011, 141:199 200.

36. Van Gorp H, Van Breemen W, Delputte PL, Nauwynck HJ: Sialoadhesin and CD163 join forces during entry of the porcine reproductive and respiratory syndrome virus. J Gen Virol 2008, 89:2943 2953.

37. Zimmermann JJ, Jacobs AC, Hermann JR, Muoz-Zanial C, Prickett JR, Roof MB, Yoon KJ: Stability of Porcine reproductive and respiratory syndrome virus at ambient temperatures. J Vet Diagn Invest 2010, 22(2):257 260.